EUCTR2007-001871-13-BE进行中（未招募）不适用
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with two doses of Lu AA21004 in patients with Major Depressive Disorder. - Not applicable
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient who meets all the following criteria, both at the Screening Visit and at the Baseline I Visit, is eligible for inclusion in this study:
- •1.The patient is able to read and understand the Subject Information Sheet.
- •2.The patient has signed the Informed Consent Form. No study-related procedures may be performed before the patient has signed the form
- •3.The patient has a major depressive episode (MDE) as the primary diagnosis according to DSM-IV TR criteria (classification code 296.xx).
- •4.The reported duration of the current MDE is at least 4 weeks.
- •5.The patient had at least one other MDE before the current episode.
- •6.The patient has a MADRS total score equal or higher than 26
- •7.The patient is man or woman, aged between 18 and 75 years (extremes included).
- •8.The patient, if female, must:
- •-agree not to try to become pregnant during the study, AND
- •-use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicide, or condom for male partner in combination with spermicide), OR
- •-have had her last natural menstruation at least 24 months prior to baseline, OR
- •-have been surgically sterilised prior to baseline, OR
- •-have had a hysterectomy prior to baseline, OR
- •-not be sexually active with men
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The patient has one or more of the following conditions:
- •-Any current psychiatric disorder other than MDD as defined in the DSM-IV-TR (assessed with the M.I.N.I.).
- •-Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
- •-Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
- •-Presence or history of a clinically significant neurological disorder (including epilepsy).
- •-Neurodegenerative disorder (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington´s disease, etc.).
- •-Any axis II disorder that might compromise the study.
- •2.The patient has a significant risk of suicide according to the investigator’s opinion or has a score equal or higher than 5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
- •3.The current depressive symptoms of the patient are considered by the investigator to have been resistant to two adequate antidepressant treatments of at least 6 weeks duration.
- •4.The patient has used or uses disallowed recent or concomitant medication (specified in Appendix II, Recent and Concomitant Medication), or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
- •5.The patient has received electroconvulsive therapy within 6 months prior to screening.
- •6.The patient is currently receiving formal cognitive or behavioural therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
- •7.The patient has a clinically significant unstable illness, for example, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, skin and subcutaneous tissue disorders or metabolic disturbance.
- •8.The patient has clinically significant abnormal vital signs.
- •9.The patient has a history of severe drug allergy or hypersensitivity, or clinically significant lactose intolerance.
- •10.The patient has one or more laboratory values outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant.
- •11.The patient has TSH value outside the normal range at Screening Visit.
- •12.The patient has a clinically significant abnormal ECG.
- •13.The patient has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability or efficacy.
- •14.The patient has been treated with any investigational medicinal product within 30 days or 5 half lives (whichever is longer) prior to screening.
- •15.The patient is pregnant or breast-feeding.
- •16.The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
- •17.The patient is a member of the site personnel or their immediate families.
- •18.The patient has previously participated in this study.
- •19.The patient has previously been exposed to Lu AA21004.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, multi-centre study toassess the efficacy and safety of adjunctive zonisamide in paediatric partial onsetseizures - CATZEpilepsyEUCTR2006-002515-27-HUEisai Ltd266
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizuresEUCTR2007-003557-91-HUEisai Limited154
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD) - Not applicableEUCTR2008-001673-15-EEH. Lundbeck A/S600
进行中（未招募）
1 期
A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.Estudio en doble ciego, aleatorizado, controlado con placebo y multicéntrico, dirigido a evaluar la eficacia y la seguridad del tratamiento adyuvante con zonisomida en las crisis mioclónicas asociadas a la epilepsia generalizada idiopáticaEUCTR2007-003556-10-ESEisai Limited4
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with two doses of Lu AA21004 in patients with Major Depressive Disorder. - Not applicableEUCTR2007-001871-13-DEH. Lundbeck A/S500